Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sanolium publishes bond prospectus and applies for listing of its bonds on Nasdaq Stockholm

Sanolium AB (publ) (the "Company" or "Sanolium") has issued a senior secured bond loan of SEK 1,000,000,000 on 15 March 2024, within a total framework amount of SEK 1,500,000,000, on the Swedish bond market (the "Bonds"). The Bonds carry a floating interest rate of STIBOR 3m + 4.00 per cent. per annum and matures 15 March 2029. The Company will apply for listing of the Bonds on the Corporate Bond list at Nasdaq Stockholm. The Bonds will be admitted to trading at Nasdaq Stockholm as soon as possible. In connection with this, the Company has prepared a prospectus. The prospectus has

On 24 April 2024, Nurminen Logistics Plc’s board of directors has decided, with the authorization of the annual general meeting, to pay an equity repayment of EUR 0.02 per share

Nurminen Logistics Plc      Stock Exchange Release April 25, 2024, at 4.15 pm On April 24, 2024, Nurminen Logistics Plc's board of directors, with the authorization of the annual general meeting, has decided to pay an equity repayment of EUR 0.02 per share for each of the company's 78,127,855 outstanding shares, i.e. a total of EUR 1,562,557.10. The equity repayment ex-date for the installment shall be 25 April 2024, the record date shall be 26 April 2024, and the equity repayment date shall be 3 May 2024. Nurminen Logistics Plc For more information, please contact Olli Pohjanvirta,

Committees of Metso’s Board of Directors

Metso Corporation’s stock exchange release on April 25, 2024, at 4:05 p.m. EESTThe Board of Directors of Metso Corporation held its organizing meeting after the Annual General Meeting held earlier today. In the organizing meeting, the Board of Directors elected the members of the Audit & Risk Committee and the Remuneration & HR Committee from among its members. Arja Talma was reappointed as Chair of the Audit & Risk Committee and Klaus Cawén, Terhi Koipijärvi, Ian W. Pearce and Emanuela Speranza as its members. Reima Rytsölä was reappointed as Chair of the Remuneration & HR

Norconsult is part of the winning team for the new airport terminal in Bodø

Sandvika, 25 April (OSE: NORCO) Norconsult Norge, together with the contractor Hent, has secured a contract with Avinor to design and build the buildings at the new airport in Bodø, Norway. Norconsult will act as a subcontractor to Hent, in collaboration with Archus and LPO architects. The Integrated Project Delivery contract includes the construction of the buildings at the new airport: The terminal building, including office spaces, and operational buildings with a total of 25,000 m2. “Norconsult will contribute to the construction of a new and contemporary airport dimensioned and

Dedicare updates profitability target for 2024

Dedicare has had a financial profitability target of its EBIT margin exceeding 7.0 percent. Its Board of Directors has decided to change its profitability target to an EBITA margin of 7.0 percent over time.   Dedicare’s strategy is acquisition-led growth. The reason for this change is to enable the monitoring of profitability performance without the effect of acquisition-related assets. The transfer to an EBITA-based metric is also consistent with how other major staffing and consulting firms monitor their profitability targets, so it increases comparability with other companies on

Dedicare adjusts segment reporting

Dedicare is changing the allocation of costs in its segment structure from its First-quarter Interim Report 2024 onwards. In the previous segment reporting, shareholder-related expenses were allocated between all segments. Effective the first quarter 2024, all these expenses will be reported in the Group-wide segment. Shareholder expenses are costs arising due to ownership/management of shares and the company’s listing on Nasdaq. Dedicare’s opinion is that all these expenses should be charged to the Group-wide segment to give a fairer view. Segment reporting for 2023 has been recalculated

Interim report January – March 2024: Shifting up a gear

With its robust financial position and ambitious objectives, Catena has the prerequisites for further growth and development.25 April 2024 3.00 p.m CEST · Rental income rose by 11 percent to SEK 493 million (446). · Net operating surplus increased by 10 percent to SEK 394 million (359). · Profit from property management rose by 3 percent to SEK 285 million (278). · Profit from property management per share is SEK 5.58 (5.58). · The change in value of properties was SEK -199 million (-710). · Profit for the period rose to SEK 120 million (-444), corresponding to an

T-Mobile and EQT Announce Joint Venture to Acquire Lumos and Build Out the Un-carrier’s First Fiber Footprint

T-Mobile’s scalable broadband and wireless growth engine combined with EQT’s infrastructure expertise will leverage Lumos' fiber platform to deliver broadband services to more AmericansBELLEVUE, Wash. & NEW YORK, NY, April 25, 2024,  -- T-Mobile (NASDAQ: TMUS), America's 5G leader and fastest growing broadband provider, and EQT , a purpose-driven global investment organization, today announced they have entered into a joint venture (JV) with EQT’s Infrastructure VI fund (EQT) that will acquire fiber-to-the-home platform Lumos 

The Cross-Border Payments 100 reveals the world’s most important payments providers

· Today, FXC Intelligence published The 2024 Cross-Border Payments 100 .  · Now in its sixth year, the Cross-Border Payments 100 is published annually to celebrate the most important players in the cross border payments industry. · With over 15,000 players in the cross border payments space, the companies that make the list have to fulfill a strict criteria.Today, FXC Intelligence published The 2024 Cross-Border Payments 100 

Interim Report 1 January – 31 March 2024: A challenging start to 2024

First quarter 2024 • Net sales SEK 430.2 million (503.2) • EBITA SEK 17.4 million (41.6) • EBITA margin 4.0 percent (8.3) • EBIT SEK 15.1 million (38.0) • EBIT margin 3.5 percent (7.6) • Profit after financial items SEK 13.5 million (31.3) • Profit for the period SEK 10.5 million (24.5) • Basic earnings per share SEK 1.09 (2.57) • Diluted earnings per share SEK 1.08 (2.55)     Performance measures     Chief Executive Officer’s statement   It was a challenging start on all Nordic markets in 2024, and the first quarter of the year

Giant BidCo publishes a supplement to the offer document for the public cash offer to the shareholders of Byggfakta

THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE AND IN THE

La Française des Jeux SA publishes supplement to the offer document in respect of the recommended public offer to the shareholders of Kindred Group plc

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in

Resolutions of Metso Corporation’s Annual General Meeting

Metso Corporation’s stock exchange release on April 25, 2024, at 3:50 p.m. EESTMetso Corporation’s Annual General Meeting (AGM) was held today, April 25, 2024, in Helsinki. Adoption of the financial statements The AGM adopted the financial statements for the financial year 2023 and resolved to grant the members of the Board of Directors and President and CEO discharge from liability for the financial year January 1 to December 31, 2023. Dividend for 2023 The AGM resolved to approve the Board of Directors’ proposal to pay a dividend of EUR 0.36 per share for the financial year

Škoda Transtech’s engineering and documentation department’s operations in Oulu, Finland will be partially transferred to Etteplan

ETTEPLAN OYJ, Press Release, 25.4.2024 at 3.45 p.m. (EEST) Škoda Transtech’s engineering and documentation department’s operations in Oulu, Finland will be partially transferred to Etteplan Etteplan and Škoda Transtech have agreed on the partial transfer of the engineering and documentation department’s operations of Škoda Transtech in Oulu, Finland to Etteplan. According to the agreement, 21 employees from Škoda Transtech will join Etteplan as existing employees as of May 1, 2024. The agreement is related to Škoda Transtech's concluded change negotiations. Based on the newly

Smoltek publishes a filmed interview with the company’s CTO Farzan Ghavanini

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB (“Smoltek”) has published a filmed interview with the company's CTO Farzan Ghavanini. In the interview, Farzan talks, among other things, about the company's latest technical progress for the CNF-MIM technology and what remains to be done in order to be able to compete with today's leading technology for ultra-thin capacitors.Group company Smoltek Semi has recently completed a new technology generation for the company's capacitor technology,

OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs

Stockholm, Sweden – April 25 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the release of a report outlining the opportunity to address critical Unmet Medical Needs in oncology care.Pain remains one of the leading reasons for cancer treatment interuptions and significantly impacts Quality of Life during chemotherapy and radiotherapy. BupiZenge™ is uniquely positioned to help millions of patients, alleviating their oral pain stemming from oral mucositis, a common and debilitating side

Hunter Group ASA - Annual General Meeting held on 25 April 2024

Oslo, 25 April 2024 The Annual General Meeting ("AGM") in Hunter Group ASA (the "Company") took place today on 25 April 2024 at 10:00 hours CET. All resolutions were passed in accordance with the proposals set out in the notice for the AGM. The minutes from the AGM are attached to this announcement.  Contact: Erik A.S. Frydendal, CEO, Ph. +47 957 72 947 E-mail: ef@huntergroup.no Lars M. Brynildsrud, CFO, Ph. +47 932 60 882 E-mail: lb@huntergroup.no This stock exchange announcement is made pursuant to section 5-9 of the Norwegian Securities Trading Act.

NIB and Citadele fund Baltics’ first gene therapy manufacturing facility

The Nordic Investment Bank (NIB), Citadele bank and the Lithuanian biopharmaceutical company UAB Celltechna signed a ten-year financing agreement of EUR 37 million for a gene therapy product facility in Vilnius. NIB will provide a EUR 22.5 million loan, and Citadele will extend a EUR 14.5 million loan for the project.The new Gene Therapy Centre will be the first and so far the only one of its kind in the Baltic countries. It will provide facilities for both research and manufacturing processes, supporting the development of genetic disease treatments. Spanning approximately 8,000 square

IFS announces best Q1 results in company history with 26% increase in ARR YoY and 20% increase in Cloud revenue YoY

New CEO visits 100 customers in first 100 daysLondon, April 25, 2024 – IFS , the global cloud enterprise software company, today announced its financial results for the first quarter ending March 31, 2024. The results reflect the best start to the year in company history – an early victory for new CEO Mark Moffat, who was appointed on January 9th, 2024. Summary of Q1 results:  · Annual Recurring Revenue (ARR) up 26% YoY · Cloud Revenue up 20% YoY · Software Revenue growth up 19% YoY A steadfast customer focus positions IFS as the

Invitation to presentation of Quickbit’s Q3 ‘23/24 interim report

Quickbit will publish its interim report for the period 1 January – 31 March 2024 on Wednesday, 22 May 2024, at 08:00 am CET. On the same day at 11:00 am CET Quickbit will organize a web presentation for investors. Daniel Sonesson, CEO, and Daniel Boettge, CFO, will present and comment on the report and the development. During the presentation there will be time for questions in the web presentation. The presentation will be held in English.   The live webcast will be available at the following link: meet.google.com/cvi-zckx-btp   The presentation and report will be

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") stock exchange announcement on 9 March 2023, in which the Company announced that it had requested Atlas Special Opportunities, LLC ("Atlas") to subscribe and pay for the first tranche of convertible bonds under the Investment Agreement entered into between Atlas and the Company, consisting of 75 convertible bonds. Atlas has, by a notice of conversion, requested conversion of convertible bonds with a nominal value of NOK 500,000 which, pursuant to the bond terms, are convertible into 182,844 new shares in the Company at a

Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity

Oslo, 25 April 2024. Lytix Biopharma announces that the Norwegian Medical Products Agency has approved the clinical trial application for a Phase II Neoadjuvant study in early-stage melanoma, a severe form of skin cancer. In this study, Lytix`s lead candidate LTX-315 will be given in combination with another type of immunotherapy before surgery. The study is called NeoLIPA and will be led by Dr. Henrik Jespersen, Head of Melanoma Oncology at Radiumhospitalet (Oslo University Hospital).   “We are very excited to start the NeoLIPA study and investigate the clinical effect of LTX-315 in

There are no items matching the current filter
There are no more items matching the current filter
Back to top